1547-12-2

Usage

Uses

Used in Pharmaceutical Industry:
Benzenamine, 4-(2-fluoroethoxy)is used as an intermediate in the production of pharmaceuticals for its ability to be incorporated into the molecular structure of various drugs. It plays a crucial role in the synthesis of active pharmaceutical ingredients, contributing to the development of new medications.
Used in Dye Industry:
In the dye industry, Benzenamine, 4-(2-fluoroethoxy)is used as a building block in the synthesis of various dyes. Its unique chemical structure allows it to be a key component in creating a wide range of colors and shades, enhancing the colorfastness and performance of dyes in different applications.
Used in Rubber Industry:
Benzenamine, 4-(2-fluoroethoxy)is utilized as an intermediate in the production of rubber accelerators. Its presence in the synthesis process helps to improve the vulcanization process, leading to enhanced rubber properties such as strength, elasticity, and durability.
Used in Organic Synthesis and Chemical Reactions:
As a versatile building block, Benzenamine, 4-(2-fluoroethoxy)is employed in various organic synthesis processes and chemical reactions. Its unique structure and reactivity make it a valuable component in the development of new chemical compounds and materials, contributing to advancements in various industries.

Upstream product

• 54840-15-2 4-N-tert-butoxycarbonylaminophenol 
• 123-30-8 4-amino-phenol 
• 1609428-90-1 tert-butyl (4-(2-fluoroethoxy)phenyl)carbamate 
• 100-02-7 4-nitro-phenol 
• 103-90-2 4-acetaminophenol 
• 714-24-9 4-acetamidophenyl 2-fluoroethyl ether 

Downstream Products

• 915287-82-0 [2-[3-(4-(2-fluoro-ethoxy)-phenyl)-ureido]-ethyl]-carbamic acid t-butyl ester 
• 1609428-95-6 ethyl 1-(4-(2-fluoroethoxy)phenyl)-1H-1,2,3-triazole-4-carboxylate 
• 1609428-98-9 1-(4-(2-fluoroethoxy)phenyl)-1H-1,2,3-triazole-4-carboxylic acid 
• 1609428-41-2 N-(4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl)-1-(4-(2-fluoroethoxy)phenyl)-1H-1,2,3-triazole-4-carboxamide 
• 1335465-83-2 4,6-dichloro-3-((3-(4-(2-fluoroethoxy)phenyl)-2,4-dioxoimidazolidin-1-yl)methyl)-indole-2-carboxylic acid 
• 1335465-75-2 ethyl 4,6-dichloro-3-((3-(4-(2-fluoroethoxy)phenyl)-2,4-dioxoimidazolidin-1-yl)methyl)-indole-2-carboxylate 
• 1335465-65-0 ethyl 4,6-dichloro-3-((3-(4-(2-fluoroethoxy)phenyl)-1-(2-methoxy-2-oxoethyl)ureido)methyl)-indole-2-carboxylate 
• 135016-31-8 2-Ethyl-6-(2-fluoroethoxy)-4-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methoxy]quinoline hydrochloride 

Relevant academic research and scientific papers

Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins

The present invention relates to novel compounds that can be employed in the diagnosis, treatment, alleviation or prevention of a group of disorders and abnormalities associated with amyloid proteins and amyloid-like proteins, such as Alzheimer's disease. Precursors for the preparation of the compounds according to the present invention are also provided.

Synthesis and evaluation of novel F-18-labeled pyrimidine derivatives: Potential FAK inhibitors and PET imaging agents for cancer detection

Based on computer-assisted drug design, a series of novel pyrimidine derivatives was successfully synthesized and characterized by 1H NMR, 13C HNMR, and MS spectra. All the new compounds were evaluated for their activity against focal adhesion kinase and showed low IC50 values in comparison with control drugs. In particular, for compound 8i, its IC50 value was 0.060 μM, suggesting its advantage as a focal adhesion kinase inhibitor. To evaluate the potentiality of these compounds as PET imaging agents in cancer detection, compounds 8a, 8c, 8h, and 8i were successively labeled with 18F. The four 18F-labeled pyrimidine derivatives showed appropriate log P values and high stability in physiological saline and mouse plasma. Noticeably, compound [18F]-8a with a 4-methoxyl group at the benzene ring exhibited good in vivo biodistribution data in mice bearing the S180 tumor, which promoted a further microPET imaging study of compound [18F]-8a. The microPET image of [18F-8a] administered into the S180 tumor-bearing mice acquired at 60 min post-injection illustrated that the uptake in S180 tumor was obvious. These results suggested that compound [18F]-8a might be a new probe for PET tumor imaging.

CARBAZOLE AND CARBOLINE COMPOUNDS FOR USE IN THE DIAGNOSIS, TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH AMYLOID OR AMYOLID-LIKE PROTEINS

The present invention relates to novel compounds that can be employed in the diagnosis, treatment, alleviation or prevention of a group of disorders and abnormalities associated with amyloid proteins and amyloid-like proteins, such as Alzheimer's disease. Precursors for the preparation of the compounds according to the present invention are also provided.

Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands

Two novel classes of compounds targeting the sigma-2 (σ2) receptor were synthesized, and their bioactivities to binding σ1 and σ2 receptors were measured. Four novel triazole carboxamide analogues, 24d, 24e, 24f, and 39c, demonstrated high affinity and selectivity for the σ2 receptor. These data suggest 11C-labeled versions of these compounds may be potential σ2-selective radiotracers for imaging the proliferative status of solid tumors.

Compounds for binding and imaging amyloid plaques and their use

The present invention relates to novel compounds (3-aminopropen-1-ones) useful for binding and imaging beta amyloid deposits and their use in detecting or treating Alzheimer's disease and amyloidosis.

Synthesis, labelling and evaluation of hydantoin-substituted indole carboxylic acids as potential ligands for positron emission tomography imaging of the glycine binding site of the N-methyl- d -aspartate receptor

The N-methyl- d-aspartate (NMDA) receptor as a type of ionotropic glutamatergic receptors is essential for physiological processes such as learning, memory and synaptic plasticity. A glutamate-induced overactivation of these receptors, accompanied by increased intracellular calcium concentration, causes cell injury and leads to a large number of acute or chronic neurological disorders, such as stroke, trauma, Parkinson's disease and Alzheimer's disease. In an attempt to visualise the glutamatergic neurotransmission in vivo with positron emission tomography, novel fluoroethoxy- and methoxy-substituted reference compounds based on the lead structure of a hydantoin-substituted indole-2-carboxylic acid were synthesised. The affinities towards the glycine binding site of the NMDA receptor showed Ki values between 322 and 11 nM and the lipophilicities ranged from logD values of 1.51 to 2.53. On the basis of these results, precursor compounds were synthesised containing a phenolic hydroxy moiety to obtain the radiolabelled ligands through an alkylation reaction. Radiosynthesis was achieved by labelling the precursor ethyl 4,6-dichloro-3-((3-(4-hydroxyphenyl)-2,4-dioxoimidazolidin-1-yl)methyl)- indole-2-carboxylate with 2-[18F]fluoroethyl tosylate or [ 11C]methyl iodide and subsequent cleavage of the ethyl ester moiety. This gave the final products in overall decay-corrected radiochemical yields of 5-7% and 6-9% and specific activities of 24-67 GBq/μmol and 8-26 GBq/μmol, respectively. Copyright

Synthesis of an 18F-labelled high affinity β1- adrenoceptor PET radioligand based on ICI 89,406

To date, some non-selective β-adrenoceptor (β-AR) positron emission tomography (PET) radioligands are in clinical use, but no PET radioligand for the selective imaging of cardiac β1-ARs is clinically available. Therefore, the aim of this study